Effect of secukinumab on quality of life and psoriasis‐related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52‐week study
Sign Up to like & getrecommendations! Published in 2018 at "Journal of the American Academy of Dermatology"
DOI: 10.1016/j.jaad.2017.10.025
Abstract: Background: Secukinumab has demonstrated greater sustained skin clearance than ustekinumab through week 52, greater improvement in symptoms and health‐related quality of life, and comparable safety profile. Objective: To assess the impact of secukinumab versus that… read more here.
Keywords: versus ustekinumab; psoriasis related; psoriasis; quality life ... See more keywords